Chugai Pharmaceutical Japan was founded in 1925. Chugai’s biopharmaceutical and antibody technologies take a leading position in the industry in Japan currently. In 1994 Chugai’s business began in China with Granocyte® (granulocyte-colony stimulating factor; G-CSF) launch. Aiming to become a top pharmaceutical company, in March 2014 Chugai Pharma China Co., Ltd. was established with the main function of import, manufacturing and sales/marketing. On the 1st of July 2015, Chugai Pharma China Co., Ltd. and Chugai Pharma (Shanghai) Consulting Co., Ltd. integrated into Chugai Pharma China in order to strengthen the pharmaceutical operation for getting further business development in China.
Oncology, cardiovascular and bone/joint diseases are positioned as Chugai Pharm China’s strategic areas where we accelerate introducing the new products into China market to contribute to the benefit of the medical community and human health in China.
Chugai’s mission is to dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world. Our vision is to become a top innovator and sustainable patient-centric healthcare, powered by our unique strengths in science and technology. We will continue to meet our goals to fulfill our mission.
We would appreciate your understanding and continuous supports on our efforts and activities.